0801726c-9faf-4905-8cd9-71ad4fc3df25
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 77
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.430
- G2M_CHECKPOINT+0.410
- MITOTIC_SPINDLE+0.410
- E2F_TARGETS+0.330
- ALLOGRAFT_REJECTION+0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.280
- MTORC1_SIGNALING+0.280
- ANDROGEN_RESPONSE+0.270
- APICAL_JUNCTION+0.270
- HEDGEHOG_SIGNALING+0.260
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.470
- DNA_REPAIR-0.240
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.240
- ADIPOGENESIS-0.200
- INTERFERON_ALPHA_RESPONSE-0.160
- UV_RESPONSE_UP-0.140
- TNFA_SIGNALING_VIA_NFKB-0.120
- PEROXISOME-0.040
- HEME_METABOLISM-0.030
- MYC_TARGETS_V1-0.030
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-3263 | Med | Medulloblastoma | 0.782 |
| 2 | TCGA-BH-A1FU-01A-11R-A14D-07 | — | C | 0.736 |
| 3 | TCGA-CV-6959-01A-11R-1915-07 | — | — | 0.728 |
| 4 | TCGA-A1-A0SN-01A-11R-A144-07 | — | C | 0.723 |
| 5 | 20140163.TNBC | — | D | 0.721 |
| 6 | SRR27320688 | — | — | 0.716 |
| 7 | TCGA-85-8353-01A-21R-2296-07 | — | cohortSQ1 | 0.715 |
| 8 | EPT0578 | EPN | Posterior Fossa EPN | 0.712 |
| 9 | TCGA-CQ-5326-01A-01R-1873-07 | — | — | 0.712 |
| 10 | MDT-AP-1349 | Med | Medulloblastoma | 0.704 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.430 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.410 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.410 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.330 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.310 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.280 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.280 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.270 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.270 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.260 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.240 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.230 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.180 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.180 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.170 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.160 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.150 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.140 | Inavolisib | — uncovered |